Arc­turus' ex-CEO tri­umphs, oust­ing board that oust­ed him

Joe Payne

The cur­tain is falling on the epic dra­ma be­tween lit­tle San Diego biotech Arc­turus and its for­mer CEO Joe Payne. Af­ter months of har­poon­ing each oth­er with law­suits in a war for con­trol, Payne has pre­vailed.

At least that’s what we’re read­ing from a state­ment Arc­turus pub­lished to­day, which an­nounced that four board mem­bers are re­sign­ing: Stu­art Collinson, Craig Wil­lett, Daniel Gef­fken, and David Shapiro. This was the ac­tion Payne has been root­ing for, as these four di­rec­tors, he al­leged, con­spired against him — re­sult­ing in the fir­ing of Payne this Feb­ru­ary. In par­tic­u­lar, Payne said these guys en­gaged in ac­tiv­i­ty that vi­o­lat­ed the rules es­tab­lished by the Is­raeli laws that gov­ern its op­er­a­tions.

For some back­ground, Payne was fired from the RNA med­i­cines com­pa­ny for al­leged­ly putting his own in­ter­ests be­fore Arc­turus’. Payne re­ject­ed that as­ser­tion, and re­spond­ed with de­mands for the com­pa­ny to hold an ex­tra­or­di­nary gen­er­al meet­ing to vote on an ouster of his own de­sign. He want­ed to trade out the four ad­ver­saries on the board with new faces: Mag­da Mar­quet, Pe­ter Far­rell, An­drew Sas­sine, and James Bar­low.

Ac­cord­ing to Arc­turus’ new state­ment, the com­pa­ny has vot­ed in fa­vor of Payne’s plans, forc­ing the old play­ers out. The com­pa­ny’s stock is up near­ly 14% on the news, trad­ing at $6.93 per share as of press time.

Dra­ma aside, Payne’s pick for the board in­clude some of the biggest names in San Diego biotech. Mar­quet, founder and co-chair of Althea Tech­nolo­gies, is a well-known in­dus­try ex­ec­u­tive who’s been lead­ing San Diego’s biotech com­mu­ni­ty for a cou­ple of decades. And Far­rell is the founder and for­mer long-term CEO and cur­rent chair­man of ResMed, one of the largest med­ical de­vice com­pa­nies in San Diego.

It’s un­clear what will hap­pen now with Payne. Will he re­join Arc­turus af­ter the new board set­tles in? We reached out to Payne, and will up­date you when we hear back.

The drawn out fight took a nasty turn when Arc­turus launched a se­ries of law­suits against Payne, seek­ing dam­ages and in­junc­tive re­lief and de­tail­ing Payne’s mul­ti­ple al­leged mis­con­ducts. Those in­clud­ed op­er­at­ing a “lu­cra­tive side busi­ness dur­ing busi­ness hours” and at­tempt­ing to trans­fer Arc­turus’ IP for no ap­par­ent rea­son dur­ing his tenure, in ad­di­tion to or­ches­trat­ing a move to block Arc­turus’ rou­tine au­dit­ing ac­tiv­i­ty.

But now, those law­suits should be dropped. Ac­cord­ing to Arc­turus’ state­ment, the set­tle­ment agree­ment in­clud­ed “mu­tu­al re­leas­es of all par­ties and the agree­ment by the com­pa­ny and Joseph E. Payne to ter­mi­nate all pend­ing lit­i­ga­tion.”

Hope­ful­ly the next news we hear from Arc­turus will be about the com­pa­ny’s sci­ence.

“We are pleased to have come to­geth­er to reach this very pos­i­tive out­come that al­lows Arc­turus to move for­ward, fo­cused on cre­at­ing sub­stan­tial val­ue for all share­hold­ers,” Payne said. “We warm­ly ap­pre­ci­ate the con­tin­ued sup­port from our share­hold­ers, and the en­cour­age­ment to reach an am­i­ca­ble res­o­lu­tion through this agree­ment. The com­pa­ny has ac­com­plished a great deal in the last five years, and I’m con­fi­dent that with the strong lead­er­ship of the board and man­age­ment team, the best days are ahead for Arc­turus.”

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA has vowed not to let politics overrule science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped the FDA and other health agencies under his purview of their rule making ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Anthony Coyle (Repertoire)

Flag­ship's merged biotech Reper­toire nets ex-Pfiz­er CSO An­tho­ny Coyle as R&D chief

Flagship is building a big-name C-suite at its new, $220 million merged biotech.

Repertoire Immune Medicines, which already boasts former Bioverativ chief John Cox as its CEO, announced yesterday that Anthony Coyle, the former Pfizer CSO and the founding CEO of Pandion, will join as their head of R&D.

“As we progress clinical trials for our multi-clonal T cell candidates in immuno-oncology, Tony’s deep expertise in cellular immunology and novel therapeutic development will help us achieve our vision of creating a new class of transformative medicines for patients,” Cox said in a statement.

Samit Hirawat (Bristol Myers Squibb)

Af­ter bruis­ing re­jec­tion, blue­bird and Bris­tol My­ers Squibb land ide-cel pri­or­i­ty re­view. But will it mat­ter for the CVR?

With the clock all but up, the FDA accepted and handed priority review to Bristol Myers Squibb and bluebird bio’s BCMA CAR-T, keeping a narrow window open for Celgene investors to still cash in on the $9 CVR from the $63 billion Celgene merger.

The acceptance comes five months after the two companies weres slammed with a surprise refuse-to-file that threatened to foreclose the CVR entirely. Today’s acceptance sets the FDA decision date for March 27, 2021 – or precisely 4 days before the CVR deadline of March 31. Given the breakthrough designation and strong pivotal data — 81.5% response rate, 35.2% complete response rate — priority review was largely expected.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.

President Donald Trump (via AP Images)

Signs of an 'Oc­to­ber Vac­cine Sur­prise' alarm ca­reer sci­en­tists. HHS con­tin­ues to claim Azar “will de­fer com­plete­ly to the FDA"

President Donald Trump, who seems intent on announcing a Covid-19 vaccine before Election Day, could legally authorize a vaccine over the objections of experts, officials at the FDA and even vaccine manufacturers, who have pledged not to release any vaccine unless it’s proved safe and effective.

In podcasts, public forums, social media and medical journals, a growing number of prominent health leaders say they fear that Trump — who has repeatedly signaled his desire for the swift approval of a vaccine and his displeasure with perceived delays at the FDA — will take matters into his own hands, running roughshod over the usual regulatory process.

Can a mag­net­ic cell ther­a­py re­place corneal trans­plan­ta­tion? As eight-year jour­ney leads to the clin­ic, two broth­ers un­veil bold vi­sion

Jeff Goldberg was getting acquainted with a brand new way to do corneal transplants when an even newer, even bolder idea hit him.

It was almost 10 years ago, and Goldberg was in his first faculty position at Bascom Palmer Eye Institute at the University of Miami. Scientists had developed a new way to do cornea transplants where instead of sewing a whole donor cornea — a decades-old practice — they were just engrafting the inner layer of cells.

News brief­ing: Tiny Vac­cinex's drug flops in PhII Hunt­ing­ton's tri­al, stock craters; Siol­ta nabs $30M Se­ries B to de­vel­op mi­cro­bio­me drug

Siolta Therapeutics, a microbiome company targeting allergic diseases, raked in a $30 million Series B to develop its lead candidate, STMC-103H. The drug, which has been FDA fast-tracked, is headed for proof-of-concept trials, according to the company. Its various indications include allergic asthma, food allergies, atopic dermatitis, allergic rhinitis, and allergy prevention.

The news comes just after the California-based biotech added a prominent biopharma veteran as an advisor: 20-year Gilead CEO John Martin. The biotech also gained Richard Shames as CMO, who came by way of Protagonist Therapeutics.

Embattled CDC director Robert Redfield (AP Images)

Covid-19 roundup: CDC ad­vi­so­ry com­mit­tee de­lays pri­or­i­ty dis­tri­b­u­tion vote; EU re­port­ed­ly in­dem­ni­fy­ing vac­cine mak­ers

A federal committee that advises the CDC was expected to hold a vote Tuesday on a plan regarding the distribution for initial doses of approved Covid-19 vaccines. But that vote has been scrapped.

The Advisory Committee on Immunization Practices, or ACIP, won’t be voting until the committee members learn more about which vaccines become available first, the Wall Street Journal reported. The vote could potentially wait until a specific vaccine is authorized before recommending how to dole out the first doses.

Zai Lab hauls in $761M from Hong Kong IPO to push Ze­ju­la, more bud­ding can­di­dates in Chi­na — re­port

Zai Lab is set to net more than $761 million from its secondary listing in Hong Kong after pricing the IPO at $72.51 (HKD$562) — just a hair below its Nasdaq closing price on Monday, Bloomberg and Nikkei Asian Review reported.

A pioneer in bringing Western drugs to China, co-founder and CEO Samantha Du has more than tripled Zai Lab’s market cap in the three years it’s been public in the US. The HKEX listing is designed to fund R&D and commercialization for the current portfolio while fueling new in-licensing pacts, the biotech wrote in a filing.

Tae Han Kim, Samsung Biologics CEO (SeongJoon Cho/Bloomberg via Getty Images)

Sam­sung Bi­o­log­ics nets $330M+ deal from As­traZeneca ahead of 'Su­per Plan­t' con­struc­tion

Just a few weeks after announcing plans to construct a $2 billion “Super Plant,” Samsung Biologics is keeping its foot on the gas.

The Korean CDMO has inked a $330.8 million manufacturing contract with AstraZeneca, the companies announced Monday evening, providing the British drugmaker the ability to expand production capabilities in the Asia market. Per terms of the deal, the partnership could be increased to $545.6 million.